KALRN mutations promote antitumor immunity and immunotherapy response in cancer.
Mengyuan LiYuxiang MaYou ZhongQian LiuCanping ChenLei QiangXiao-Sheng WangPublished in: Journal for immunotherapy of cancer (2021)
The KALRN mutation is a useful biomarker for predicting the response to immunotherapy in patients with cancer.